Drug Information

Drug General Information
Drug ID
D06GUG
Former ID
DIB011359
Drug Name
BTT-1023
Synonyms
SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
Drug Type
Antibody
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 2 [524913]
Company
BioTie Therapies Corp
Target and Pathway
Target(s) Membrane copper amine oxidase Target Info [532422]
BioCyc Pathway Phenylethylamine degradation I
Spermine and spermidine degradation I
KEGG Pathway Glycine, serine and threonine metabolism
Tyrosine metabolism
Phenylalanine metabolism
beta-Alanine metabolism
Metabolic pathways
PANTHER Pathway Phenylethylamine degradation
PathWhiz Pathway Beta-Alanine Metabolism
References
Ref 524913ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
Ref 532422Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.